Founder-chairperson Kiran Mazumdar-Shaw believes the company's biggest acquisition will be a game changer for Biocon over the next decade
On National Science Day, February 28, Biocon’s founder-chairperson Kiran Mazumdar-Shaw announced the biggest acquisition in her company’s history—to purchase the biosimilars unit of long-term partner Viatris in a deal valued at up to $3.335 billion.